These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1819 related articles for article (PubMed ID: 28705205)

  • 1. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
    Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
    Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study.
    Zhang X; Ma L; Bao H; Zhang J; Wang Z; Gong P
    BMC Endocr Disord; 2014 Jul; 14():54. PubMed ID: 25001493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center.
    Lewkowicz E; Trofimiuk-Müldner M; Wysocka K; Pach D; Kiełtyka A; Stefańska A; Sowa-Staszczak A; Tomaszewska R; Hubalewska-Dydejczyk A
    Pol Arch Med Wewn; 2015; 125(5):337-46. PubMed ID: 25924181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
    Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
    Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological features and prognostic factors associated with gastroenteropancreatic mixed neuroendocrine non-neuroendocrine neoplasms in Chinese patients.
    Huang YC; Yang NN; Chen HC; Huang YL; Yan WT; Yang RX; Li N; Zhang S; Yang PP; Feng ZZ
    World J Gastroenterol; 2021 Feb; 27(7):624-640. PubMed ID: 33642833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
    Masui T; Ito T; Komoto I; Uemoto S;
    BMC Cancer; 2020 Nov; 20(1):1104. PubMed ID: 33189127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pathological characteristics and survival analysis of 355 patients with gastroenteropancreatic neuroendocrine neoplasms].
    Li Y; Wang YF; Tan BB; Er LM; Zhao Q; Fan LQ; Zhang ZD; Liu Y
    Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):426-431. PubMed ID: 32482035
    [No Abstract]   [Full Text] [Related]  

  • 9. [Analysis of primary site and pathology on 903 patients with neuroendocrine neoplasms].
    Qiu X; Liu M; Liu Q; Yang Z; Liu J; Meng F; Wang Z; Shi Y; Liu L; Zhang P; Luo J; Tan H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):993-996. PubMed ID: 28900988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute.
    Shin Y; Ha SY; Hyeon J; Lee B; Lee J; Jang KT; Kim KM; Park YS; Park CK
    Cancer Res Treat; 2015 Oct; 47(4):738-46. PubMed ID: 25687852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres.
    Frizziero M; Wang X; Chakrabarty B; Childs A; Luong TV; Walter T; Khan MS; Morgan M; Christian A; Elshafie M; Shah T; Minicozzi A; Mansoor W; Meyer T; Lamarca A; Hubner RA; Valle JW; McNamara MG
    World J Gastroenterol; 2019 Oct; 25(39):5991-6005. PubMed ID: 31660035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
    Shi H; Zhang Q; Han C; Zhen D; Lin R
    BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia.
    Ptasnuka M; Ozolins A; Narbuts Z; Truskovs A; Sperga M; Plaudis H
    World J Surg; 2020 Feb; 44(2):585-593. PubMed ID: 31605174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinicopathological features and multivariate analysis of prognostic factors for patients with gastroenteropancreatic neuroendocrine tumors].
    Wang X; Song ZF; Yao WX; Pan CC; Xiang MF; Wang H
    Zhonghua Yi Xue Za Zhi; 2013 May; 93(18):1411-4. PubMed ID: 24025507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary malignancy in patients with sporadic neuroendocrine neoplasia.
    Krausch M; Raffel A; Anlauf M; Schott M; Lehwald N; Krieg A; Kröpil F; Cupisti K; Knoefel WT
    Endocrine; 2013 Oct; 44(2):510-6. PubMed ID: 23494366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm.
    Shi H; Jiang C; Zhang Q; Qi C; Yao H; Lin R
    Diagn Pathol; 2020 Sep; 15(1):108. PubMed ID: 32917216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors of patients with gastroenteropancreatic neuroendocrine neoplasms.
    Huang PY; Tsai KL; Liang CM; Tai WC; Rau KM; Wu KL; Huang CC; Chuah SK
    Kaohsiung J Med Sci; 2018 Nov; 34(11):650-656. PubMed ID: 30392572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chinese expert consensus on gastroenteropancreatic neuroendocrine neoplasms (2022 edition)].
    Expert Committee on Neuroendocrine Neoplasms, Chinese Society of Clinical Oncology
    Zhonghua Zhong Liu Za Zhi; 2022 Dec; 44(12):1305-1329. PubMed ID: 36575783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An 11-year retrospective study: clinicopathological and survival analysis of gastro-entero-pancreatic neuroendocrine neoplasm.
    Liu H; Xie R; Zhao Z; Xu D; Yang K; Ding M; Tan D; Liao W; Han X; Zhang J; Shen D; Yuan J; Xu Z; Fei J
    Medicine (Baltimore); 2020 Aug; 99(33):e21682. PubMed ID: 32872039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 91.